苦碟子注射液治疗急性脑梗死的系统评价  

Kudiezi Injection for acute cerebral infarction: A systematic review

作　　者：刘姣[1] 夏芸[1] 路遥[1] 李新龙[1] 刘文娜[1] 

机构地区：[1]北京中医药大学东方医院,北京100078

出　　处：《北京中医药》2013年第7期497-501,共5页Beijing Journal of Traditional Chinese Medicine

基　　金：国家重点基础研究发展计划(973计划)项目(2012CB518406);国家科技重大专项"重大新药创制"项目(2009ZX09502-030);北京中医药大学科研创新团队项目(2011-CXTD-23)

摘　　要：目的系统评价苦碟子注射液治疗急性脑梗死(ACI)的疗效和安全性。方法运用Cochrane系统评价方法收集国内2002—2012年间发表的苦碟子注射液治疗ACI的随机对照试验(RCT),评价苦碟子注射液的疗效及临床辨证用药情况。结果根据检索策略共检索到文献208篇,最终纳入RCT 26篇。Meta分析结果显示,病死率苦碟子组与西药组比较组间差异无统计学意义[RR=0.63,95%C(I0.19,2.09),P>0.05];神经功能缺损评分苦碟子组与空白对照组比较组间差异有统计学意义[RR=-2.23,95%C(I-3.74,-0.71),P<0.05]、苦碟子组与其他中药注射液组比较组间差异有统计学意义[RR=-4.51,95%C(I-6.06,-2.97),P<0.05]。结论苦碟子注射液对改善ACI神经功能缺损可能有效,但目前临床上该药治疗ACI尚缺乏辨证使用。Objective To systematically evaluate the efficacy and safety of Kudiezi Injection for acute cerebral infarction （ACI）. Methods By means of Cochrane systematic review, randomized controlled trials （RCTs） on Kudiezi Injection treating ACI from 2002 to 2012 were collected. The efficacy and syndrome differentiation for using Kudiezi Injection in clinical were evaluated. Results 208 pub lications were retrieved by search strategy and a total of 26 RCTs were included. According to the Meta analysis, there was no significant betw een-group difference in mortality between Kudiezi Injection group and Western medicine group （RR=0.63, 95%CI [0.19, 2.09], P 〉0.05）; as for the score of National Institutes of Health Stroke Scale （NIHSS）, there was significant between-group difference when comparing Kudiezi Injection group with blank control group （RR=-2.23,95% CI [-3.74,-0.71], P 〈0.05）,as well as with other Chinese medicine injection groups（RR=-4.51,95 %CI[-6.06,-2.97],P 〈0.05）. Conclusion Kudiezi Injection might have effect on improving neurologic deficit of ACI, however, the use of syndrome differentiation is lacking in treating ACI with this injection in clinical at present.

关 键 词：苦碟子注射液 急性脑梗死 系统评价 

分 类 号：R277.7[医药卫生—中医学]